NYSE · Healthcare · Drug Manufacturers—General
Pfizer Inc. (PFE)
As of Sep 25, 4:01 PM ET, Pfizer (PFE) last traded at $28.67, up 0.92% on the day. Its TickerHum research score is 51/100 (average). It reported revenue of $63.7B for the twelve months ending 2026-06-28, down 0.2% year over year.
Ratings
- Valuation: 75/100 — Strongest input: price / sales (ttm) 2.6x. Weakest: price / earnings (ttm) 37.7x.
- Growth: 12/100 — Strongest input: revenue growth (ttm, yoy) -0.2 %. Weakest: diluted eps growth (ttm, yoy) -59.8 %.
- Profitability: 36/100 — Strongest input: net margin 6.8 %. Weakest: return on equity 5.1 %.
- Financial health: 34/100 — Strongest input: long-term debt / equity 0.71. Weakest: cash / long-term debt 0.02.
- Momentum: 67/100 — Strongest input: 3-month return +18.0 %. Weakest: 6-month return +4.0 %.
- Attention: 54/100 — Strongest input: headlines in the last 7 days 42. Weakest: volume vs 3-month average 0.7x.
- Risk: 83/100 — Strongest input: annualised volatility (1y) 23.5 %. Weakest: max drawdown (1y) -17.1 %.
- Data confidence: 89/100 — Strongest input: latest financial period age (days) 61 d. Weakest: quote age (hours) 45 h.
Reported fundamentals
| Metric | Value | Period |
|---|---|---|
| Revenue | $63.7B | TTM ending 2026-06-28 · 10-Q |
| Revenue growth | -0.2% | TTM ending 2026-06-28 · 10-Q |
| Net income | $4.33B | TTM ending 2026-06-28 · 10-Q |
| Diluted EPS | $0.76 | TTM ending 2026-06-28 · 10-Q |
| Net margin | 6.8% | TTM ending 2026-06-28 · 10-Q |
| Free cash flow | $10.99B | TTM ending 2026-06-28 · 10-Q |
| Cash | $976M | as of 2026-06-28 · 10-Q |
| Long-term debt | $60.5B | as of 2026-06-28 · 10-Q |
| Debt / equity | 0.71 | as of 2026-06-28 · 10-Q |
Source: SEC EDGAR XBRL company facts (CIK 0000078003).
Prices: Yahoo Finance (public) — Free public Yahoo Finance data. Prices may be delayed and are for information only.